Page 138 - Read Online

Ibrahim et al ALDHs and prostate cancer

178. Cojoc M, Peitzsch C, Kurth I, Trautmann F, Kunz-Schughart LA, Markey SP, Saito K. Acquired resistance of leukemic cells to AraC is
Telegeev GD, Stakhovsky EA, Walker JR, Simin K, Lyle S, Fuessel associated with the upregulation of aldehyde dehydrogenase 1 family
S, Erdmann K, Wirth MP, Krause M, Baumann M, Dubrovska A. member A2. Exp Hematol 2013;41:597-603.e2.
Aldehyde dehydrogenase is regulated by beta-catenin/TCF and 194. Lee DH, Chung K, Song JA, Kim TH, Kang H, Huh JH, Jung SG,
promotes radioresistance in prostate cancer progenitor cells. Cancer Ko JJ, An HJ. Proteomic identification of paclitaxel-resistance
Res 2015;75:1482-94. associated hnRNP A2 and GDI 2 proteins in human ovarian cancer
179. Condello S, Morgan CA, Nagdas S, Cao L, Turek J, Hurley TD, cells. J Proteome Res 2010;9:5668-76.
Matei D. beta-Catenin-regulated ALDH1A1 is a target in ovarian 195. Sun QL, Sha HF, Yang XH, Bao GL, Lu J, Xie YY. Comparative
cancer spheroids. Oncogene 2015;34:2297-308. proteomic analysis of paclitaxel sensitive A549 lung adenocarcinoma
180. Wikstrom P, Stattin P, Franck-Lissbrant I, Damber JE, Bergh A. cell line and its resistant counterpart A549-Taxol. J Cancer Res Clin
Transforming growth factor beta1 is associated with angiogenesis, Oncol 2011;137:521-32.
metastasis, and poor clinical outcome in prostate cancer. Prostate 196. Barr MP, Gray SG, Hoffmann AC, Hilger RA, Thomale J, O’Flaherty
1998;37:19-29. JD, Fennell DA, Richard D, O’Leary JJ, O’Byrne KJ. Generation and
181. Hellsten R, Johansson M, Dahlman A, Sterner O, Bjartell A. characterisation of cisplatin-resistant non-small cell lung cancer cell
Galiellalactone inhibits stem cell-like ALDH-positive prostate cancer lines displaying a stem-like signature. PLoS One 2013;8:e54193.
cells. PLoS One 2011;6:e22118. 197. Sladek NE, Kollander R, Sreerama L, Kiang DT. Cellular levels of
182. Kroon P, Berry PA, Stower MJ, Rodrigues G, Mann VM, Simms M, aldehyde dehydrogenases (ALDH1A1 and ALDH3A1) as predictors
Bhasin D, Chettiar S, Li C, Li PK, Maitland NJ, Collins AT. JAK- of therapeutic responses to cyclophosphamide-based chemotherapy
STAT blockade inhibits tumor initiation and clonogenic recovery of of breast cancer: a retrospective study. Rational individualization of
prostate cancer stem-like cells. Cancer Res 2013;73:5288-98. oxazaphosphorine-based cancer chemotherapeutic regimens. Cancer
183. Tanei T, Morimoto K, Shimazu K, Kim SJ, Tanji Y, Taguchi T, Chemother Pharmacol 2002;49:309-21.
Tamaki Y, Noguchi S. Association of breast cancer stem cells 198. Sreerama L, Sladek NE. Identification and characterization of a
identified by aldehyde dehydrogenase 1 expression with resistance to novel class 3 aldehyde dehydrogenase overexpressed in a human
sequential Paclitaxel and epirubicin-based chemotherapy for breast breast adenocarcinoma cell line exhibiting oxazaphosphorine-specific
cancers. Clin Cancer Res 2009;15:4234-41. acquired resistance. Biochem Pharmacol 1993;45:2487-505.
184. Sladek NE. Aldehyde dehydrogenase-mediated cellular relative 199. Moreb JS, Mohuczy D, Ostmark B, Zucali JR. RNAi-mediated
insensitivity to the oxazaphosphorines. Curr Pharm Des 1999;5:607-25. knockdown of aldehyde dehydrogenase class-1A1 and class-3A1 is
185. Moreb JS, Schweder M, Gray B, Zucali J, Zori R. In vitro selection specific and reveals that each contributes equally to the resistance
for K562 cells with higher retrovirally mediated copy number against 4-hydroperoxycyclophosphamide. Cancer Chemother
of aldehyde dehydrogenase class-1 and higher resistance to Pharmacol 2007;59:127-36.
4-hydroperoxycyclophosphamide. Hum Gene Ther 1998;9:611-9. 200. Parajuli B, Fishel ML, Hurley TD. Selective ALDH3A1 inhibition by
186. Wulf GG, Wang RY, Kuehnle I, Weidner D, Marini F, Brenner MK, benzimidazole analogues increase mafosfamide sensitivity in cancer
Andreeff M, Goodell MA. A leukemic stem cell with intrinsic drug cells. J Med Chem 2014;57:449-61.
efflux capacity in acute myeloid leukemia. Blood 2001;98:1166-73. 201. Marcato P, Dean CA, Pan D, Araslanova R, Gillis M, Joshi M, Helyer
187. Todaro M, Alea MP, Di Stefano AB, Cammareri P, Vermeulen L, L, Pan L, Leidal A, Gujar S, Giacomantonio CA, Lee PW. Aldehyde
Iovino F, Tripodo C, Russo A, Gulotta G, Medema JP, Stassi G. dehydrogenase activity of breast cancer stem cells is primarily due
Colon cancer stem cells dictate tumor growth and resist cell death by to isoform ALDH1A3 and its expression is predictive of metastasis.
production of interleukin-4. Cell Stem Cell 2007;1:389-402. Stem Cells 2011;29:32-45.
188. Ma S, Lee TK, Zheng BJ, Chan KW, Guan XY. CD133+ HCC cancer 202. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB,
stem cells confer chemoresistance by preferential expression of the Dewhirst MW, Bigner DD, Rich JN. Glioma stem cells promote
Akt/PKB survival pathway. Oncogene 2008;27:1749-58. radioresistance by preferential activation of the DNA damage
189. Hermann PC, Huber SL, Herrler T, Aicher A, Ellwart JW, Guba M, response. Nature 2006;444:756-60.
Bruns CJ, Heeschen C. Distinct populations of cancer stem cells 203. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer:
determine tumor growth and metastatic activity in human pancreatic role of ATP-dependent transporters. Nat Rev Cancer 2002;2:48-58.
cancer. Cell Stem Cell 2007;1:313-23. 204. Kondo T, Setoguchi T, Taga T. Persistence of a small subpopulation
190. Croker AK, Allan AL. Inhibition of aldehyde dehydrogenase (ALDH) of cancer stem-like cells in the C6 glioma cell line. Proc Natl Acad
activity reduces chemotherapy and radiation resistance of stem-like Sci U S A 2004;101:781-6.
ALDHhiCD44(+) human breast cancer cells. Breast Cancer Res 205. Smith PJ, Wiltshire M, Chappell SC, Cosentino L, Burns PA, Pors K,
Treat 2012;133:75-87. Errington RJ. Kinetic analysis of intracellular Hoechst 33342--DNA
191. Honoki K, Fujii H, Kubo A, Kido A, Mori T, Tanaka Y, Tsujiuchi T. interactions by flow cytometry: misinterpretation of side population
Possible involvement of stem-like populations with elevated ALDH1 status? Cytometry A 2013;83:161-9.
in sarcomas for chemotherapeutic drug resistance. Oncol Rep 206. Hilton J. Role of aldehyde dehydrogenase in cyclophosphamide-
2010;24:501-5. resistant L1210 leukemia. Cancer Res 1984;44:5156-60.
192. Landen CN Jr, Goodman B, Katre AA, Steg AD, Nick AM, Stone 207. Friedman HS, Colvin OM, Kaufmann SH, Ludeman SM, Bullock
RL, Miller LD, Mejia PV, Jennings NB, Gershenson DM, Bast RC N, Bigner DD, Griffith OW. Cyclophosphamide resistance in
Jr, Coleman RL, Lopez-Berestein G, Sood AK. Targeting aldehyde medulloblastoma. Cancer Res 1992;52:5373-8.
dehydrogenase cancer stem cells in ovarian cancer. Mol Cancer Ther 208. Sreerama L, Sladek NE. Cellular levels of class 1 and class 3 aldehyde
2010;9:3186-99. dehydrogenases and certain other drug-metabolizing enzymes in
193. Kawasoe M, Yamamoto Y, Okawa K, Funato T, Takeda M, Hara human breast malignancies. Clin Cancer Res 1997;3:1901-14.
T, Tsurumi H, Moriwaki H, Arioka Y, Takemura M, Matsunami H, 209. Abdullah LN, Chow EK. Mechanisms of chemoresistance in cancer

16 Journal of Cancer Metastasis and Treatment ¦ Volume 4 ¦ Aug 21, 2018